Evommune (EVMN) Share-based Compensation (2024 - 2026)

Evommune (EVMN) has 3 years of Share-based Compensation data on file, last reported at $35.9 million in Q1 2026.

• On a quarterly basis, Share-based Compensation changed N/A year-over-year to $35.9 million in Q1 2026; TTM through Mar 2026 was $35.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $38.6 million, up 2141.58% from the prior year.
• Share-based Compensation for Q1 2026 stood at $35.9 million, up from $1.1 million in the prior quarter.
• Over the last five years, Share-based Compensation for EVMN reached as high as $35.9 million in Q1 2026 and fell as low as $401000.0 in Q3 2024.
• Historically, Share-based Compensation has averaged $8.7 million across 3 years, with a median of $1.1 million in 2025.
• On a YoY basis, Share-based Compensation climbed as much as 39.9% in 2025 and fell as far as 80.02% in 2025.
• Year by year, Share-based Compensation stood at $5.5 million in 2024, then plunged by 80.02% to $1.1 million in 2025, then jumped by 3166.61% to $35.9 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $35.9 million in Q1 2026, $1.1 million in Q4 2025, and $561000.0 in Q3 2025.